Answers are grounded in this paper and cite their sources.
A new Schiff base ligand (E)-2-((7-hydroxy-4-methyl-2-oxo-2H-chromen-8-yl)methylene)-N-(5- methyl-3-phenyl-1H-indol-2-yl)hydrazine carboxamide (L) (3) was synthesized by the reaction of N-(5-methyl-3-phenyl-1H-indol-2-yl)hydrazinecarboxamide (1) and 7-hydroxy-4-methyl-2-oxo-2Hchromene- 8-carbaldehyde (2). The Cu(II), Co(II), Ni(II) and Zn(II) metal complexes (4a-d) were synthesized and its structural elucidation was done by different spectral techniques. The Schiff base (3) behaves as ONO donor ligand and forms the complexes of the sort [M(L)(Cl)(H2O)2] for Cu(II) (4a) and Zn(II) (4d) and [M(L)2] for Co(II) (4b) and Ni(II) (4c). Compounds (3) and (4a-d) were tested in vitro for antimicrobial action, cytotoxicity property against Artemia salina and anti-tuberculosis assay against Mycobacterium tuberculosis (ATCC 25177). The metal complexes showed very good biological activity.
No takes yet. Share an insight, caveat, or question.
Nalini et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: